STERIS plc $STE Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC cut its stake in shares of STERIS plc (NYSE:STE) by 4.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 45,684 shares of the medical equipment provider’s stock after selling 2,356 shares during the period. Segall Bryant & Hamill LLC’s holdings in STERIS were worth $11,304,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in STE. Elo Mutual Pension Insurance Co purchased a new stake in STERIS during the third quarter valued at about $2,480,000. Journey Strategic Wealth LLC lifted its stake in shares of STERIS by 43.4% in the 3rd quarter. Journey Strategic Wealth LLC now owns 1,616 shares of the medical equipment provider’s stock valued at $400,000 after purchasing an additional 489 shares in the last quarter. Rafferty Asset Management LLC lifted its stake in shares of STERIS by 5.1% in the 3rd quarter. Rafferty Asset Management LLC now owns 10,924 shares of the medical equipment provider’s stock valued at $2,703,000 after purchasing an additional 534 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of STERIS by 0.6% during the 3rd quarter. American Century Companies Inc. now owns 547,521 shares of the medical equipment provider’s stock worth $135,479,000 after purchasing an additional 3,136 shares during the period. Finally, Generali Investments Management Co LLC increased its position in STERIS by 317.2% during the 3rd quarter. Generali Investments Management Co LLC now owns 972 shares of the medical equipment provider’s stock worth $241,000 after purchasing an additional 739 shares in the last quarter. 94.69% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have weighed in on STE. Weiss Ratings reaffirmed a “buy (b)” rating on shares of STERIS in a research report on Friday, January 9th. Wall Street Zen lowered shares of STERIS from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $275.20.

STERIS Stock Up 0.0%

Shares of NYSE:STE opened at $243.37 on Thursday. The company has a market capitalization of $23.87 billion, a price-to-earnings ratio of 33.94 and a beta of 1.05. The company has a 50 day moving average of $255.21 and a two-hundred day moving average of $251.70. STERIS plc has a 52-week low of $204.90 and a 52-week high of $269.44. The company has a quick ratio of 1.75, a current ratio of 2.48 and a debt-to-equity ratio of 0.26.

STERIS (NYSE:STE) last announced its earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share for the quarter, meeting the consensus estimate of $2.53. STERIS had a net margin of 12.15% and a return on equity of 14.34%. The firm’s revenue was up 9.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.32 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. As a group, analysts forecast that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 19th. Stockholders of record on Tuesday, February 17th will be paid a dividend of $0.63 per share. The ex-dividend date is Tuesday, February 17th. This represents a $2.52 annualized dividend and a dividend yield of 1.0%. STERIS’s dividend payout ratio (DPR) is currently 35.15%.

STERIS Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.